November 18, 2024 02:34 PM EST

CSL Behring will close California office as part of shrinking ex vivo work

Max Bayer

Pharma Reporter

CSL Behring is closing a Pasadena, CA-based R&D site and moving the operations to Massachusetts as part of a larger repositioning of the company’s gene …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CSL Behring will close California office as part of shrinking ex vivo work

Max Bayer

Pharma Reporter

Sign up to read this article for free.

A rare neurological disease is Sage’s last, best hope after failures in depression

Novartis strikes radiopharma deal with Ratio worth up to $745M

Rocket shares promising long-term results from rare heart disease gene therapy in small study

FDA offers more guidance on developing cell and gene therapies

Scottish biotech debuts with ‘Trojan horse’ platform for cancer

Are programs with compounded GLP-1s safe for your population?

CSL Behring will close Cal­i­for­nia of­fice as part of shrink­ing ex vi­vo work

Max Bayer

Pharma Reporter

Sign up to read this article for free.

A rare neu­ro­log­i­cal dis­ease is Sage’s last, best hope af­ter fail­ures in de­pres­sion

No­var­tis strikes ra­dio­phar­ma deal with Ra­tio worth up to $745M

Rock­et shares promis­ing long-term re­sults from rare heart dis­ease gene ther­a­py in small study

FDA of­fers more guid­ance on de­vel­op­ing cell and gene ther­a­pies

Scot­tish biotech de­buts with ‘Tro­jan horse’ plat­form for can­cer

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

CSL Behring will close California office as part of shrinking ex vivo work

A rare neurological disease is Sage’s last, best hope after failures in depression

Novartis strikes radiopharma deal with Ratio worth up to $745M

Rocket shares promising long-term results from rare heart disease gene therapy in small study

FDA offers more guidance on developing cell and gene therapies

Scottish biotech debuts with ‘Trojan horse’ platform for cancer

Are programs with compounded GLP-1s safe for your population?